This collaboration reflects Bharat Biotech’s continued commitment to global public health and equitable vaccine access ...

Bharat Biotech has in-licensed GSK's Shigella vaccine candidate, altSonflex1-2-3, aimed at combating Shigellosis in young ...

Shares of GSK PLC GSK rose 1.74% to £15.50 Thursday, on what proved to be an all-around favorable trading session for the stock market, with the FTSE 100 Index UKX rising 0.23% to 8,884.92. GSK PLC ...

Bharat Biotech and GSK collaborate to advance Shigella vaccine, aiming to combat urgent public health threat globally.

GSK is putting the finishing touches on its case for antibody-drug conjugate Blenrep with a key progression-free survival ...

Hyderabad-based Bharat Biotech will lead Phase 3 trials, regulatory progress and manufacturing for Shigella vaccine ...

Hyderabad based vaccine maker Bharat Biotech International Limited (BBIL) has in-licensed a potential vaccine candidate for ...

Bharat Biotech and GSK plc have partnered to develop a vaccine for Shigellosis, a severe bacterial diarrhea. The altSonflex1-2-3 vaccine candidate, developed by GSK, will be further developed by ...

Bharat Biotech and GSK collaborate to develop a vaccine for Shigellosis, a severe form of bacterial diarrhea. The innovative ...

Bharat Biotech International Limited (BBIL), a global leader in vaccine innovation and manufacturing, announced on Thursday that it has partnered with GSK plc, a global biopharma company, for the ...

GSK said it licensed its Shigella vaccine candidate, altaltSonflex1-2-3, to Bharat Biotech International.